References
Bigal ME, Lipton RB (2006) Modifiable risk factors for migraine progression. Headache 46(9):1334–1343
Andrasik F, Flor H, Turk DC (2005) An expanded view of psychological aspects in head pain: the biopsychosocial model. Neurol Sci 26:S87–S91
Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, Loupe PS, Burstein R, Newman LC, Lipton RB (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14(11):1081–1090
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
We certify that there is no actual or potential conflict of interest in relation to this article.
Ethical standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Grazzi, L., D’Amico, D. Chronic migraine and medication overuse: which strategy for a complex scenario. Neurol Sci 40 (Suppl 1), 175–176 (2019). https://doi.org/10.1007/s10072-019-03829-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-019-03829-z